幹細胞治療の世界市場予測（～2021年）：同種幹細胞、自己幹細胞...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 GEOGRAPHIC SCOPE 16
1.3.3 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 18

2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 21
2.1.2.1 Key data from primary sources 21
2.1.2.2 Breakdown of primaries 21
2.2 MARKET SIZE ESTIMATION 22
2.2.1 BOTTOM-UP APPROACH 22
2.2.2 TOP-DOWN APPROACH 23
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.4 RESEARCH ASSUMPTIONS 25

3 EXECUTIVE SUMMARY 26
3.1 INTRODUCTION 26
3.2 CONCLUSION 29

4 PREMIUM INSIGHTS 30
4.1 STEM CELL THERAPY MARKET OVERVIEW 30
4.2 REGIONAL ANALYSIS: STEM CELL THERAPY MARKET, BY TYPE,
2016 VS. 2021 (USD MILLION) 31
4.3 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2016–2021 (USD MILLION) 32
4.4 REGIONAL ANALYSIS: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2016 VS. 2021 (USD MILLION) 33
 

5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 MARKET GROWTH DRIVERS 36
5.2.1.1 Growing awareness related to the therapeutic potency of stem cells in effective disease management 36
5.2.1.2 Development of advanced genome-based cell analysis techniques 37
5.2.1.3 Increasing public-private investments for the development of stem cell therapies 37
5.2.1.4 Development in infrastructure related to stem cell banking and processing 38
5.2.2 MARKET RESTRAINTS 38
5.2.2.1 Unclear regulatory guidelines for product development & commercialization 38
5.2.2.2 Socio-ethical issues related to the use of ESCs in disease treatment 39
5.2.3 MARKET GROWTH OPPORTUNITIES 39
5.2.3.1 Supportive regulations across developing countries 39
5.2.3.2 Emergence of iPSCs as an effective alternative to ESCs 40
5.2.4 MARKET CHALLENGES 41
5.2.4.1 Technical limitations related to production scale-up 41
5.3 REGULATORY LANDSCAPE 41
5.3.1 NORTH AMERICA 41
5.3.2 EUROPE 42
5.3.3 ASIA-PACIFIC 44
5.3.4 REST OF THE WORLD 45

6 INDUSTRY INSIGHTS 46
6.1 INTRODUCTION 46
6.2 SUPPLY CHAIN ANALYSIS 46
6.2.1 KEY STAKEHOLDERS 47
6.2.2 KEY INFLUENCERS 47
6.3 PIPELINE ANALYSIS 48
6.3.1 PIPELINE ANALYSIS: BASED ON PHASE OF CLINICAL STUDY 48
6.3.2 PIPELINE ANALYSIS: BASED ON TYPE 49
6.3.3 PIPELINE ANALYSIS: BASED ON THE CELL LINE USED 50

7 GLOBAL STEM CELL THERAPY MARKET, BY TYPE 52
7.1 INTRODUCTION 53
7.2 ALLOGENEIC STEM CELL THERAPY MARKET, BY APPLICATION 54
7.2.1 MUSCULOSKELETAL DISORDERS 55
7.2.2 WOUNDS AND INJURIES 57
7.2.3 SURGERIES 57
7.2.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 58
7.2.5 OTHER APPLICATIONS 59
7.3 AUTOLOGOUS STEM CELL THERAPY MARKET, BY APPLICATION 59
7.3.1 WOUNDS AND INJURIES 61
7.3.2 CARDIOVASCULAR DISEASES 62
7.3.3 GASTROINTESTINAL DISEASES 63
7.3.4 OTHER APPLICATIONS 64

8 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 65
8.1 INTRODUCTION 66
8.2 MUSCULOSKELETAL DISORDERS 67
8.3 WOUNDS AND INJURIES 68
8.4 CARDIOVASCULAR DISEASES 69
8.5 SURGERIES 70
8.6 GASTROINTESTINAL DISEASES 71
8.7 OTHER APPLICATIONS 72

9 GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE 73
9.1 INTRODUCTION 74
9.2 ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS 75
9.3 BONE MARROW-DERIVED MESENCHYMAL STEM CELLS 75
9.4 CORD BLOOD/EMBRYONIC STEM CELLS 76
9.5 OTHER CELL SOURCES 77

10 STEM CELL THERAPY MARKET, BY REGION 78
10.1 INTRODUCTION 79
10.2 NORTH AMERICA 79
10.3 EUROPE 83
10.4 ASIA-PACIFIC 86
10.5 REST OF THE WORLD (ROW) 89

11 COMPETITIVE LANDSCAPE 92
11.1 OVERVIEW 92
11.2 MARKET RANKING 92
11.3 STRATEGIC BENCHMARKING 93
11.3.1 PRODUCT DEVELOPMENT AND COMMERCIALIZATION 93
11.4 COMPETITIVE SCENARIO 94
11.5 RECENT DEVELOPMENTS 95
11.5.1 PRODUCT LAUNCHES AND APPROVALS 95
11.5.2 EXPANSIONS 96
11.5.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 97
 

12 COMPANY PROFILES 98
12.1 INTRODUCTION 98
12.1.1 GEOGRAPHIC BENCHMARKING 98
(Overview, Financials, Products & Services, Strategy, and Developments)*
12.2 OSIRIS THERAPEUTICS, INC. 99
12.3 MEDIPOST CO., LTD. 101
12.4 ANTEROGEN CO., LTD. 104
12.5 PHARMICELL CO., LTD. 105
12.6 HOLOSTEM TERAPIE AVANZATE SRL 107
12.7 JCR PHARMACEUTICALS CO., LTD. 108
12.8 NUVASIVE, INC. 110
12.9 RTI SURGICAL, INC. 111
12.10 ALLOSOURCE 112
*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted companies.

13 APPENDIX 113
13.1 INSIGHTS OF INDUSTRY EXPERTS 113
13.2 DISCUSSION GUIDE 114
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 116
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 118
13.5 AVAILABLE CUSTOMIZATIONS 119
13.6 RELATED REPORTS 119
13.7 AUTHOR DETAILS 120